Bridgette Heller, Merck EVP and president of its consumer care division, adjured life-sci managers to enable women to unleash the full power of their knowledge and ideas to drive growth in the business.
Physician trust in pharmaceutical brands is driven by an emotional connection as well as functional attributes and perceptions of the manufacturer, said Harris Interactive, which found Advair, Spiriva and Mirena to be tops in their categories with doctors.
Hologic alleges KV has botched the marketing and wants rights to the drug. KV disagrees.
A government-funded study looks at whether patients with breast cancer really need 12 months of the treatment.
Sales of Teva's MS blockbuster Copaxone are likely to peak this year before giving way as more therapeutic options become available, a Teva exec says.
Endo is restructuring, bringing its four operating units under the same corporate roof and rebranding to reflect its diversification out of its origins in pain and urology drugs.
The FDA issued guidance clarifying narrow questions of scientific or generic name placement in ads and labeling in different media, including electronic media.
GlaxoSmithKline divested North American OTC drugs worth about $200 million in sales, a portfolio that seemed like a good strategic fit for buyer Prestige Brands Holdings.
Branded drug sales declined 0.7% to $229 billion last year, according to IMS Health, and that's having an impact on promotional spend.
Marketers working on Pfizer brands Viagra and Chantix, and AstraZeneca's Nexium, can pat themselves on the back, since they all scored in the "genius" percentile based on digital marketing competency, according to the L2 Digital IQ Index.
Many big pharma firms are running e-samples, a form of marketing which researchers say capitalizes on patients seeking health information and may affect prescribers' preference for brands over generics.
UCB launched a multifaceted campaign for its Cimzia injectable, calling on patients and doctors to publicly educate others about Crohn's disease and treatment.
If you still haven't entered the MM&M Awards 2009, then you'd better move fast--today (June 5) is the final deadline for submissions.
AstraZeneca will help Abbott reach more physicians with its Trilipix (fenofibric acid) drug, a cholesterol product approved by FDA last December. The companies also filed an NDA for Certriad, a Trilipix/Crestor combination drug.
Watson launched a campaign today for its overactive bladder product Gelnique - the first topical gel indicated for the disorder - featuring younger, active women.
Consumers worldwide overwhelmingly prefer medicines that have been around a long time to the latest treatments, and over half prefer generics to branded drugs given the choice, according to a DDB Health survey.
Consumers purchasing GSK's weight loss drug Alli will receive a free copy of Wynonna Judd's new album "Sing," beginning in March.
McCann Worldgroup is launching a health and wellness experiential marketing practice under the umbrella of its Momentum network.
The product site for Sanofi-Aventis's insulin injection Lantus received the highest mark in terms of consumer satisfaction, according to a Manhattan Research study.
Pfizer passed Chantix creative work to McGarryBowen, ending McCann HumanCare's contract on the smoking cessation drug, agency sources confirmed.
As part of its $1.415 billion settlement for off-label marketing of Zyprexa, Eli Lilly & Co. will enter a Corporate Integrity Agreement with the HHS Office of Inspector General.
Merck KGaA has tapped TBWA on three of its consumer healthcare brands: Nasivin, Femibion and Flexagil.
Pfizer resumes DTC advertising for Lipitor, without Robert Jarvik.
A new study identifies the top 10 product sites visited by primary care physicians.
Researches involved in the litigation against Vioxx claim the product's ADVANTAGE trials were based on marketing objectives rather than scientific rigor.
Advair outperformed Singulair in patients suffering from asthma and seasonal allergies, according to a study conducted by the National Jewish Medical Research Center.
Sudler & Hennessey (S&H) has been selected by AstraZeneca as the global agency partner of record for the developmental arthritis treatment PN400.
AstraZeneca is going for the jugular - or rather, the carotid - with new ads emphasizing Crestor's effectiveness at slowing the progression of atherosclerosis.
David Paragamian emphasizes the importance of building master brands and exploring promotional channels
AstraZeneca's Nexium could face generic competition much sooner than expected, and would-be investors should be wary, said brokerage firm Sanford C. Bernstein in an analyst note.
- Novartis psoriasis drug approval could upend market
- Sandoz gets ready to make the biosimilar case with oncologists
- Guidemark Health jumpstarts rebrand, brings on big-agency grad
- MM&M's 5 minutes with: Mark Rothera, chief commercial officer, PTC Therapeutics
- Nurse practitioner workforce has just about doubled